1500 Participants Needed

Registry for Breast Cancer and BRCA Mutations

(PROGECT Trial)

Recruiting at 13 trial locations
KS
JS
Overseen ByJoshua Staley
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: University of Kansas Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on creating a registry for individuals with Triple Negative Breast Cancer (TNBC) or those with genetic mutations linked to breast and ovarian cancer, such as BRCA1 or BRCA2. The goal is to gather information to enhance understanding of these conditions and potentially improve future treatments. Individuals diagnosed with TNBC within the last five years or those carrying certain genetic mutations may be suitable candidates. Participants can have any stage of cancer or be healthy carriers of the mutation. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could shape future treatment options.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about the Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry because it focuses on gathering critical data to better understand these aggressive cancer types. Unlike traditional treatments that directly target tumors, this registry aims to compile detailed genetic information that could unlock new insights into how these cancers develop and progress. By studying hereditary factors and genetic mutations, researchers hope to pave the way for more personalized and effective treatments in the future. This effort could lead to breakthroughs in targeted therapies, improving outcomes for patients with these challenging conditions.

Who Is on the Research Team?

PS

Priyanka Sharma, MD

Principal Investigator

University of Kansas Medical Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Triple Negative Breast Cancer
ER/PR <10% and HER negative per current ASCO/CAP guidelines
Stages I-IV
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Collection of cancer-related information from patients with triple negative breast cancer and hereditary genetic mutations

Ongoing

Follow-up

Participants are monitored for safety and effectiveness after data collection

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Registry

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Kansas Medical Center

Lead Sponsor

Trials
527
Recruited
181,000+